Maxine Gowen - Jun 6, 2024 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
Director
Signature
/s/ Matthew Rothman, Attorney-in-Fact
Stock symbol
ACRS
Transactions as of
Jun 6, 2024
Transactions value $
$0
Form type
4
Date filed
6/10/2024, 04:15 PM
Previous filing
Jun 4, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRS Stock Option (Right to Buy) Award $0 +15.8K $0.00 15.8K Jun 6, 2024 Common Stock 15.8K $1.03 Direct F1, F2
transaction ACRS Restricted Stock Units Award $0 +4.79K $0.00 4.79K Jun 6, 2024 Common Stock 4.79K Direct F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option will vest in twelve equal monthly installments commencing July 6, 2024, subject to Reporting Person's continuous service through each such date.
F2 This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy.
F3 Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F4 The shares underlying these restricted stock units will vest on June 6, 2025, subject to the Reporting Person's continuous service through such date.